NCT06345599尚未招募1 期
Phase I+Phase II Clinical Study of PRaG Therapy in Combination With Chemotherapy (AG Regimen) for Neoadjuvant Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)
Second Affiliated Hospital of Soochow University0 个研究点目标入组 66 人开始时间: 2024年5月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 66
- 主要终点
- Adverse events
研究概览
简要总结
The goal of this clinical trial is to learn about Phase I+Phase II Clinical Study of PRaG Therapy in Combination With Chemotherapy (AG Regimen) for Neoadjuvant Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study).The main question it aims to answer is to investigate the safety and efficacy of the PRaG treatment modality combined with chemotherapy neoadjuvant therapy for locally advanced pancreatic cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 ≤ 75 years；no gender limitations
- •Histopathologically and/or cytologically confirmed ductal adenocarcinoma of the pancreas, the patient has fresh pathological tissue and the tumour is located in the head and neck or body of the pancreas
- •Locally advanced pancreatic cancer, borderline resectable or unresectable, without metastases.
- •Life expectancy >= 3 months.
- •ECOG score 0-
- •Have at least 1 measurable lesion according to RECIST 1.1 criteria.
- •No prior treatment with abdominal radiotherapy, chemotherapy and PD-1/PD-L1 antibody.
- •Adequate organs functions as defined by the following laboratory values (completed within 14 days prior to registration): (1) haemoglobin >= 90 g/L (no blood transfusion within 14 days)； (2) neutrophil count > 1.5x10^9/L； (3) platelet count >= 100x10^9/L； (4) total bilirubin <= 1.5xULN (upper limit of normal)； (5) blood glutamic transferase (ALT) or blood glutamic transferase (AST) <= 2.5xULN (6) endogenous creatinine clearance >= 60 ml/min (Cockcroft's AST). (ALT) or blood albumin transaminase (AST) <= 2.5xULN； (6) endogenous creatinine clearance >= 60 ml/min (Cockcroft-Gault formula)； (7) cardiac Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) >= 50%. (8) International normalised ratio (INR) of prothrombin time ≤ 1.5 and partial thromboplastin time (APTT) ≤ 1.5 times the upper limit of normal in patients who have not received anticoagulation. Patients receiving full or parenteral anticoagulant therapy may enter a clinical trial as long as the dose of anticoagulant has been stable for at least 2 weeks prior to entry into the clinical study and the results of coagulation assays are within the limits of local therapy.
- •No congestive heart failure, unstable angina, unstable arrhythmia in the last 6 months.
- •No previous severe haematopoietic, cardiac, pulmonary, hepatic or renal abnormalities or immunodeficiencies.
- •Patient must be able to understand the potential risks and benefits associated with this study. Patient able to give informed consent and would likely to comply with the study parameters.
排除标准
- •Pregnant or breastfeeding women
- •Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and cervical cancer in situ.
- •Patients with a history of uncontrolled epilepsy, central nervous system disease or psychiatric disorders whose clinical severity, in the judgement of the investigator, may prevent the signing of informed consent or affect the patient's adherence to drug therapy.
- •Severe heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or worse congestive heart failure or severe arrhythmia requiring pharmacological intervention, or a history of myocardial infarction within the last 12 months.
- •Organ transplants requiring immunosuppressive therapy
- •Active infection or, in the investigator's judgement, significant haematological, renal, metabolic, gastrointestinal, endocrine function or metabolic disorders, or other serious uncontrolled concomitant disease
- •Allergy to any of the study drug ingredients
- •History of immunodeficiency, including HIV-positive or other acquired or congenital immunodeficiency diseases, or history of organ transplantation, or other immune-related diseases requiring long-term oral hormone therapy
- •During acute or chronic tuberculosis infection (patients with a positive T-spot test and suspicious tuberculosis foci on chest radiographs).
- •Other conditions considered by the investigator to be unsuitable for enrolment.
研究组 & 干预措施
Experimental group
Experimental
Radiotherapy、Immunotherapy、Chemotherapy
干预措施: Radiotherapy (Radiation)
结局指标
主要结局
Adverse events
时间窗: 36 months
From the beginning of treatment, record the treatment-related toxic reactions that occur in patients.
Serious adverse events
时间窗: 36 months
From the start of treatment, record any severe adverse reactions that occur in the patient.
1-year overall survival
时间窗: The 1-year overall survival rate of patients after receiving treatment
Record the 1-year overall survival rate of patients after receiving treatment
次要结局
- R0 resection rate(36 months)
- Objective response rate(36 months)
- Disease control rate(36 months)
- Overall survival(36 months)
- Progression free survival(36 months)
研究者
相似试验
已完成
2 期
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.High Risk Proliferative Diabetic RetinopathyDiabetes Mellitus Type IDiabetes Mellitus Type IINCT01281098Association for Innovation and Biomedical Research on Light and Image22
已完成
2 期
An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation TherapyLocally Recurrent Prostate CancerNCT00686088Sophiris Bio Corp30
招募中
2 期
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast CancerMetastatic Breast CancerAdvanced Breast CancerNCT04924699Shanghai Miracogen Inc.350
招募中
4 期
PRGF-ENDORET® Infiltrations in the Treatment of Low Back Pain.Diseases [C] - Musculoskeletal Diseases [C05NCT06715085Biotechnology Institute IMASD48
终止
2 期
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast CancerTriple-Negative Breast CancerNCT04958785Gilead Sciences92